{"entity":{"id":"nct05642455","kind":"trial","name":"SPEARHEAD-3 Pediatric Study","aka":[],"tldr":"A phase 1/2 trial of Afamitresgene autoleucel in osteosarcoma, run by USWM CT, LLC, now recruiting.","summary":"SPEARHEAD-3 Pediatric Study is a phase 1/2 interventional study registered as NCT05642455 by USWM CT, LLC, with 20 participants planned, started 2023-09-01 and due to reach its primary completion in 2026-10-01. Interventions recorded: Afamitresgene autoleucel. Conditions listed: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma (NBL), Osteosarcoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05642455","url":"https://clinicaltrials.gov/study/NCT05642455"}],"tags":["ctgov-ingest"],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":["afamitresgene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05642455","phase":"1/2","setting":"A Phase 1/2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors","sponsor":"USWM CT, LLC","enrolled":20,"outcomes":[]},"route":"/trials/nct05642455/","neighbours":{"cancer":[{"id":"osteosarcoma","kind":"cancer","name":"Osteosarcoma","route":"/cancers/osteosarcoma/"}],"drug":[{"id":"afamitresgene-autoleucel","kind":"drug","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/"}]}}